Clinical, Virological Characteristics, and Outcomes of Treatment with Sofosbuvir/Ledipasvir in Two Pediatric Patients Infected by HCV Genotype 4

Cells. 2019 May 5;8(5):416. doi: 10.3390/cells8050416.

Abstract

Direct-acting antiviral drugs to cure infections with Hepatitis C virus (HCV) achieve a sustained virological response (SVR) in more than 90% of adult patients. At present, clinical trials are ongoing and real-life data are still limited in children. Herein, we report two cases of pediatric patients treated with fixed-dose combination of sofosbuvir/ledipasvir, already approved to treat HCV4 genotype. Both young girls achieved SVR even though HCV4 isolates carried L28M and M31L NS5A resistance-associated substitutions (RASs). Therefore, possible effects of these RASs merit further study, especially in children.

Keywords: Hepatitis C virus 4; pediatric patients; sofosbuvir/ledipasvir.

Publication types

  • Case Reports

MeSH terms

  • Adolescent
  • Benzimidazoles / pharmacology
  • Benzimidazoles / therapeutic use*
  • Child
  • Drug Resistance, Viral / drug effects
  • Drug Resistance, Viral / genetics
  • Female
  • Fluorenes / pharmacology
  • Fluorenes / therapeutic use*
  • Follow-Up Studies
  • Genotype
  • Hepacivirus / drug effects
  • Hepacivirus / genetics*
  • Hepatitis C / drug therapy*
  • Hepatitis C / virology*
  • Humans
  • Phylogeny
  • Sofosbuvir / pharmacology
  • Sofosbuvir / therapeutic use*
  • Treatment Outcome
  • Viral Nonstructural Proteins / chemistry
  • Viral Nonstructural Proteins / metabolism

Substances

  • Benzimidazoles
  • Fluorenes
  • Viral Nonstructural Proteins
  • ledipasvir
  • Sofosbuvir